Charles Schwab Investment Management Inc. Trims Stock Position in Phibro Animal Health Corporation $PAHC

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Phibro Animal Health Corporation by 13.1% during the first quarter, owning approximately $5.4 million worth of shares after the sale.
• Phibro Animal Health reported $0.57 earnings per share for the last quarter, surpassing analysts' expectations of $0.52, with revenue of $378.7 million.
• The company announced a quarterly dividend of $0.12, payable on September 24th, representing an annualized yield of 1.5%.

Charles Schwab Investment Management Inc. lessened its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 13.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 252,606 shares of the company's stock after selling 38,050 shares during the period. Charles Schwab Investment Management Inc. owned about 0.62% of Phibro Animal Health worth $5,396,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of PAHC. Envestnet Asset Management Inc. purchased a new stake in shares of Phibro Animal Health in the 4th quarter worth approximately $219,000. Raymond James Financial Inc. purchased a new stake in Phibro Animal Health during the fourth quarter valued at approximately $1,103,000. Barclays PLC lifted its position in Phibro Animal Health by 4.4% during the fourth quarter. Barclays PLC now owns 149,643 shares of the company's stock valued at $3,142,000 after acquiring an additional 6,306 shares during the last quarter. State of Tennessee Department of Treasury lifted its position in Phibro Animal Health by 19.3% during the fourth quarter. State of Tennessee Department of Treasury now owns 19,523 shares of the company's stock valued at $410,000 after acquiring an additional 3,153 shares during the last quarter. Finally, Hsbc Holdings PLC lifted its position in Phibro Animal Health by 53.5% during the fourth quarter. Hsbc Holdings PLC now owns 17,709 shares of the company's stock valued at $372,000 after acquiring an additional 6,169 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Stock Performance

Shares of NASDAQ PAHC traded down $1.39 during midday trading on Monday, reaching $37.07. The company had a trading volume of 644,926 shares, compared to its average volume of 323,934. The business's 50-day simple moving average is $29.34 and its 200 day simple moving average is $24.45. The stock has a market cap of $1.50 billion, a P/E ratio of 31.42, a P/E/G ratio of 0.54 and a beta of 0.88. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $38.83. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. The business had revenue of $378.70 million during the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 3rd. Phibro Animal Health's dividend payout ratio (DPR) is 40.68%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their target price for the company from $25.00 to $35.00 in a research report on Monday, July 7th. Bank of America increased their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research report on Friday. Zacks Research cut shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Thursday. BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price for the company in a research report on Monday, June 16th. Finally, Wall Street Zen raised shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Phibro Animal Health currently has an average rating of "Reduce" and a consensus target price of $28.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.